Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Overview

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Full Title of Study: “A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Treatment
  • Study Primary Completion Date: October 3, 2003

Detailed Description

The duration of treatment is 8 weeks.

Interventions

  • Drug: MK0869, aprepitant
  • Drug: Comparator: placebo

Clinical Trial Outcome Measures

Primary Measures

  • HAMD-17 total score; Tolerability

Secondary Measures

  • CGI-I Scale score; Sheehan Disability Scale

Participating in This Clinical Trial

Patients with Major Depressive Disorder

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Merck Sharp & Dohme LLC
  • Provider of Information About this Clinical Study
    • Sponsor

References

Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 Feb 1;59(3):216-23. doi: 10.1016/j.biopsych.2005.07.013. Epub 2005 Oct 24.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.